Please login to the form below
Strattera
This page shows the latest Strattera news and features for those working in and with pharma, biotech and healthcare.
Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive
Strattera (atomoxetine) and erectile dysfunction therapy Cialis (tadalafil).
Latest news
-
Shire launches long-acting ADHD drug Intuniv in UK
It is also the first alternative to Eli Lilly's non-stimulant ADHD therapy Strattera (atomoxetine) in Europe, providing another option for the approximately 10% of people with the condition who
-
Lilly feels effects of Cymbalta competition
to $588m and attention-deficit hyperactivity disorder (ADHD) drug Strattera (atomoxetine) brought in $201m, up 23 per cent.
-
Scotland first in UK to back Pfizer's Inlyta
month - along with Roche's Lucentis (ranibizumab) for pathologic myopia and Eli Lilly's attention deficit hyperactivity disorder (ADHD) therapy Strattera (atomoxetine).
-
Lilly’s Strattera wins new adult ADHD licence in UK
Adults in the UK with attention deficit hyperactivity disorder (ADHD) who were not prescribed medicine as a child will now have access to Lilly's Strattera after it was approved by ... Strattera's new licence is backed by results from clinical trials
-
Lilly's Strattera patent upheld in US
The US court of appeals has upheld the validity of Eli Lilly &Company's patent for ADHD drug Strattera. ... However, the most recent decision upholds Lilly's method-of-use patent which provides protection for Strattera until May, 2017.
Shire launches long-acting ADHD drug Intuniv in UK
Lilly feels effects of Cymbalta competition
Scotland first in UK to back Pfizer's Inlyta
Lilly’s Strattera wins new adult ADHD licence in UK
More from news
Approximately 1 fully matching, plus 15 partially matching documents found.
Latest Intelligence
-
Challenging perceptions
These classes were methylphenidate-based products like Johnson &Johnson's Concerta (methylphenidate hydrochloride) and Lilly's non-stimulant Strattera (atomoxetine).
Challenging perceptions
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Omnichannel Strategy Consultant
-
Competitive Salary
-
Senior Account Manager
-
Competitive salary offered
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Assessing the value of interim analyses in clinical trials
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
- Best practice in UK diabetes care recognised at prestigious national awards
- Live Webinar: Accelerating Revenue Cycle Performance in the Healthcare Industry
- The FDA vaccine advisory board recommends booster shots of both the J&J and Moderna vaccines
- Biogen's ALS drug tofersen misses phase 3 endpoint
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck and Ridgeback request EUA from US FDA for COVID-19 drug molnupiravir
- US demand for COVID-19 antibody treatments rising fast
- David Hunt launches independent agency The Considered
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- Sanofi’s tolebrutinib demonstrates favourable one-year tolerability in patients with relapsing forms of multiple sclerosis
PMHub
Market Access Transformation
Founded in 201, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange...
Latest intelligence
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
